PRESENTING COMPANY

SECTOR

ANALYST NOTES

Alpha Tau Medical Ltd. (NASDAQ:DRTS)

Healthcare

• 100% complete response rate (tumor disappearance) in the most recent U.S. trial results in skin cancer, led by Memorial Sloan Kettering Cancer Center in NY.

Giftify, Inc. (NASDAQ:GIFT)

Consumer

• Reaching profitability in the second half of 2025

Royalties Inc. (OTC PINK:ROYIF)

Metals & Mining

• RI/ROYIF's trifecta strategy combines the upside from the breakout of the silver price to $40-50 to monetize its silver

  asset for $5-10 million and a potential up to $25 million legal settlement on a copper-silver royalty in order to acquire cash flowing music royalties with 10-15% yields offering income stability from the IP longevity of recession-proof global hit songs.

Vox Royalty Corp. (NASDAQ:VOXR)

Metals & Mining

• Compounding, per-share returns (>90% CAGR on cash flow per share growth over past three years

Femasys Inc. (NASDAQ:FEMY)

Healthcare

• Broad product portfolio targeting multi-billion dollar markets.

Zoomcar Holdings, Inc. (NASDAQ:ZCAR)

Technology

• Bookings growth of nearly 20% y/y with five consecutive quarters of positive contribution profit

Barinthus Biotherapeutics (NASDAQ:BRNS)

Healthcare

• Significantly undervalued, trading at less than 50% of cash

Theriva Biologics, Inc. (NYSE American:TOVX)

Healthcare

• Near term catalyst - Phase 2 top line clinical data expected early Q2 2025.

Perfect Corp (NYSE:PERF)

Technology

• Over $165 million cash and cash equivalents, cashflow and net income positive, while only $190 million marketcap

Clene Inc. (NASDAQ:CLNN)

Healthcare

• Stock is currently undervalued with a similar company achieving $2B market cap post ALS drug approval

PolyPid (NASDAQ:PYPD)

Healthcare

• Polypid's lead product candidate is at the end of a Phase 3 trial - full trial recruitment expected in Q1 2025 and data expected in Q2 2025

Sona Nanotech (OTCQB:SNANF)

Healthcare

• When immunotherapy hasn't worked, Sona's therapy is applied and suddenly the immunotherapy works (like Marck's $50B Keytruda). (Merck acknowledges that Keytruda only works ~30% of the time)

MIND Technology (NASDAQ:MIND)

Marine Technology

• Strong balance sheet, debt free and simplified capital structure following conversion of preferred stock to common stock

ProPhase Labs, Inc. (NASDAQ:PRPH)

Healthcare

• Built a world-class marketing platform for DTC genomics and a range of dietary supplements.

• Multi-billion dollar potential cancer test under late-stage development.

United States Antimony Corporation (NYSE American:UAMY)

Metals & Mining

• Submitted white papers for DOD antimony expansion grants.